Company Summary - SkyePharma PLC (LSE:SKP)
34.50p
0.62p
(1.80%)
FTSE Fledgling Pharmaceuticals & BiotechnologyMarket cap: £8.260m
NEW Explore our new and improved report for SkyePharma PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Engaged in research and development, manufacture and sale of prescription pharmaceutical products
| Financials - Interim (18/8/2011) | ||
|---|---|---|
| Turnover | £m | 22.1 |
| Pre-tax Profit | £m | 0.6 |
| EPS | p | 1.60 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Frank Condella | Chairman |
| Peter Grant | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
Coruno; Lodotra; Madopar DR; Paxil CR; Pulmicort; Requip; Solaraze; Sular; Triglide; Xatra OD/Uroxatral; ZYFLO CR...
Subsidiaries
SkyePharma Holding AG; Jago Holding AG; SkyePharma AG; Jagotec AG; SkyePharma Holding Inc; SkyePharma Production SAS...
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Director/PDMR Shareholding | 03/02/2012 |
| Directorate Change | 31/01/2012 |
| Directorate Change | 31/01/2012 |
For more information
and investor relations, visit the
SkyePharma PLC company website: